Cargando…

Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity

AIM: The aim of this trial was to investigate the mechanism of action for body weight loss with semaglutide. MATERIALS AND METHODS: This randomised, double‐blind, placebo‐controlled, two‐period crossover trial investigated the effects of 12 weeks of treatment with once‐weekly subcutaneous semaglutid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blundell, John, Finlayson, Graham, Axelsen, Mads, Flint, Anne, Gibbons, Catherine, Kvist, Trine, Hjerpsted, Julie B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573908/ https://www.ncbi.nlm.nih.gov/pubmed/28266779 http://dx.doi.org/10.1111/dom.12932

Ejemplares similares

Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity
por: Hjerpsted, Julie B., et al.
Publicado: (2017)

Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes
por: Gibbons, Catherine, et al.
Publicado: (2020)

The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
por: Friedrichsen, Martin, et al.
Publicado: (2021)

A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects
por: Ikushima, Ippei, et al.
Publicado: (2018)

Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
por: Carlsson Petri, Kristin Cecilie, et al.
Publicado: (2018)

Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
por: Johansen, Pierre, et al.
Publicado: (2019)

Validation of a new hand-held electronic data capture method for continuous monitoring of subjective appetite sensations
por: Gibbons, Catherine, et al.
Publicado: (2011)

Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial
por: Shi, Aixin, et al.
Publicado: (2020)

Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment
por: Jensen, Lene, et al.
Publicado: (2018)

Semaglutide, a Once-Weekly Human GLP-1 Analog, Does Not Reduce the Bioavailability of the Combined Oral Contraceptive, Ethinylestradiol/Levonorgestrel
por: Kapitza, Christoph, et al.
Publicado: (2015)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial
por: Kapitza, Christoph, et al.
Publicado: (2017)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
por: Hunt, Barnaby, et al.
Publicado: (2019)

Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?
por: Colin, Ides M, et al.
Publicado: (2022)

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany
por: Menzen, Markus, et al.
Publicado: (2023)

Effect of BMI and Binge Eating on Food Reward and Energy Intake: Further Evidence for a Binge Eating Subtype of Obesity
por: Dalton, Michelle, et al.
Publicado: (2013)

Fat-free mass and resting metabolic rate are determinants of energy intake: implications for a theory of appetite control
por: Hopkins, Mark, et al.
Publicado: (2023)

The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
por: Vidal, Josep, et al.
Publicado: (2020)

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Improved treatment satisfaction in patients with type 2 diabetes treated with once‐weekly semaglutide in the SUSTAIN trials
por: Jendle, Johan, et al.
Publicado: (2019)

Correction: Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
Publicado: (2020)

Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
por: Garcia de Lucas, Maria Dolores, et al.
Publicado: (2022)

Efficacy and safety of once‐weekly semaglutide versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30‐week, double‐blind, phase 3a, randomized trial
por: Ji, Linong, et al.
Publicado: (2021)

Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia
por: Malkin, Samuel J. P., et al.
Publicado: (2018)

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)
por: Wilding, John P H, et al.
Publicado: (2021)

The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials
por: Alabduljabbar, Khaled, et al.
Publicado: (2022)

Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom
por: Sandhu, Hera, et al.
Publicado: (2023)

Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis
por: Nomoto, Hiroshi, et al.
Publicado: (2023)

Role of resting metabolic rate and energy expenditure in hunger and appetite control: a new formulation
por: Blundell, John E., et al.
Publicado: (2012)

Appetite Suppression and Altered Food Preferences Coincide with Changes in Appetite-Mediating Hormones During Energy Deficit at High Altitude, But Are Not Affected by Protein Intake
por: Karl, J. Philip, et al.
Publicado: (2018)

Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: Protocol for a systematic review and meta-analysis
por: Shi, Fang-Hong, et al.
Publicado: (2018)

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis
por: Lingvay, Ildiko, et al.
Publicado: (2020)

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
por: Pratley, Richard E, et al.
Publicado: (2020)

Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index
por: Yabe, Daisuke, et al.
Publicado: (2022)

Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study
por: Wolffenbuttel, Bruce H. R., et al.
Publicado: (2022)

Examination of food reward and energy intake under laboratory and free-living conditions in a trait binge eating subtype of obesity
por: Dalton, Michelle, et al.
Publicado: (2013)

Estradiol and appetite: To eat or not to eat
por: Dragano, Nathalia, et al.
Publicado: (2020)

No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects
por: Demmel, Valentin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_35qtbpec2va8a512ip77pmlsd2